HC Wainwright Issues Positive Forecast for SAB Biotherapeutics (NASDAQ:SABS) Stock Price

SAB Biotherapeutics (NASDAQ:SABS) had its target price raised by HC Wainwright from $7.00 to $10.00 in a research report released on Tuesday, MarketBeat.com reports. They currently have a buy rating on the stock.

SABS has been the subject of several other reports. Wall Street Zen downgraded SAB Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 14th. Rodman & Renshaw reaffirmed a “buy” rating and issued a $13.00 target price on shares of SAB Biotherapeutics in a research report on Monday. Chardan Capital lifted their target price on SAB Biotherapeutics from $12.00 to $14.00 and gave the company a “buy” rating in a research report on Wednesday, March 11th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of SAB Biotherapeutics in a research report on Friday, April 10th. Finally, Zacks Research downgraded SAB Biotherapeutics from a “hold” rating to a “strong sell” rating in a research report on Thursday, March 12th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $11.00.

SAB Biotherapeutics Stock Down 2.7%

Shares of SABS opened at $3.62 on Tuesday. The firm has a market cap of $184.44 million, a P/E ratio of -1.56 and a beta of 0.55. SAB Biotherapeutics has a 12-month low of $1.60 and a 12-month high of $6.60. The company’s 50-day moving average price is $3.86 and its 200 day moving average price is $3.81. The company has a current ratio of 9.46, a quick ratio of 9.46 and a debt-to-equity ratio of 0.02.

SAB Biotherapeutics (NASDAQ:SABS) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.15). On average, sell-side analysts forecast that SAB Biotherapeutics will post -1.1 earnings per share for the current year.

Hedge Funds Weigh In On SAB Biotherapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in SABS. PNC Financial Services Group Inc. acquired a new position in shares of SAB Biotherapeutics during the first quarter worth about $29,000. ADAR1 Capital Management LLC acquired a new position in shares of SAB Biotherapeutics during the third quarter worth about $30,000. Dimensional Fund Advisors LP acquired a new position in shares of SAB Biotherapeutics during the third quarter worth about $32,000. State of Wyoming acquired a new position in shares of SAB Biotherapeutics during the fourth quarter worth about $34,000. Finally, Virtu Financial LLC acquired a new position in shares of SAB Biotherapeutics during the third quarter worth about $40,000. 7.82% of the stock is owned by institutional investors and hedge funds.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.